U.S. large-cap stocks posted strong gains during the shortened week of March 30-April 2. VinFast Auto led with a 42.77% jump driven by strong EV momentum and Canadian rebates. Alcoa gained 24.12% on bullish commodities sentiment amid Middle East conflict resolution expectations. Other notable gainers included SBA Communications (23.22%), Equinox Gold (20.98%), and several precious metals miners, with gains ranging from 15-19%.

Regencell Bioscience, an early-stage bioscience company focused on traditional Chinese medicine, has seen its stock surge 21,000% over the past year despite having no marketable products or revenue. The analyst strongly advises against investing in the company due to high risks inherent in early-stage biotech with no proven drug candidates, recommending established pharmaceutical companies like Pfizer as safer alternatives.

Shareholder rights law firm Bragar Eagel & Squire is investigating potential securities law violations by Regencell Bioscience and Camping World Holdings. Regencell faces a DOJ investigation into trading practices, while Camping World disclosed prior period accounting misstatements and reported significant Q4 losses with dividend suspension.

Regencell Bioscience's extraordinary 21,000% stock surge over the past year appears disconnected from fundamentals, with the pre-commercial biotech having minimal clinical progress and expressing doubt about its ability to remain in business. In contrast, Pfizer offers a more prudent investment with its robust pipeline including promising GLP-1 candidate MET-097i, cost-cutting improvements, attractive 8.7x forward earnings valuation, and a solid 6.4% dividend yield.

Ten large-cap stocks experienced significant declines during the week of January 26-30, 2026. Unity Software fell 31.63% following CEO comments about world models amid competition from Google's Project Genie. Precious metals stocks including Hecla Mining (down 33.33%) and Coeur Mining (down 26.13%) declined after President Trump's nomination of Kevin Warsh for Fed Chair strengthened the dollar. Healthcare stocks UnitedHealth (down 17.87%) and Humana (down 26.07%) fell after analyst downgrades. Other notable losers included The Trade Desk (down 16.61%), First Majestic Silver (down 22.86%), Axon Enterprise (down 20.88%), Reddit (down 16.79%), and Regencell Bioscience (down 13.38%).

Ten large-cap stocks experienced significant declines during the week of January 12-16, 2026. Regencell Bioscience led losses with a 42.08% drop, while Trip.com fell 20.19% following a Chinese anti-monopoly investigation. Other major decliners included Atlassian (19.82%), Figma (19.41%), HubSpot (16.56%), and Intuit (14.38%), with analyst downgrades cited for several stocks.

Ten large-cap stocks surged last week driven by defense spending increases, AI infrastructure deals, and acquisition speculation. Top performers included Regencell Bioscience (89.45% gain), Revolution Medicines (51.38% on Merck acquisition talks), Kratos Defense (36.12% on military budget expansion), AeroVironment (35.86% on Army partnership), Karman Holdings (33.91% on acquisition deal), SanDisk (33.15% on pricing strategy), Bloom Energy (30.55% on credit facility), Oklo (29.04% on Meta power deal), Applied Digital (29.48% on earnings beat), and Figure Technology (29.33% on analyst upgrade).

Shareholder rights law firm Bragar Eagel & Squire is investigating Regencell Bioscience and Camping World Holdings for potential federal securities law violations. Regencell disclosed a DOJ investigation into trading of its shares in October 2025, causing an 18.56% stock decline. Camping World revealed prior period misstatements related to deferred tax assets, resulting in a 24.79% stock price drop.

Regencell Bioscience, a Hong Kong-based pharma company with no revenue, surged over 17,000% in 2025 to reach a $11 billion market cap. The dramatic rise was driven by its low public float (only ~56 million of 494 million shares publicly available), social media buzz about its Traditional Chinese Medicine treatments for ADHD and autism, algorithmic trading, and a 38-for-1 stock split. However, the company remains in R&D stage with cumulative losses of $3.58-$4.36 million annually and faces a DOJ investigation into its trading activities.

Law firm investigating potential securities law violations for Regencell and Camping World, following DOJ investigation and financial reporting discrepancies that negatively impacted stock prices.

Regencell Bioscience Holdings (RGC) experienced a massive 9,800% stock surge in 2025, but the company has zero revenue and appears to be a risky investment despite investor excitement about its focus on Traditional Chinese Medicine for neurocognitive disorders.

Law firm Bragar Eagel & Squire is investigating potential securities law violations for four companies: Regencell, Beyond Meat, Alvotech, and Camping World, following significant stock price drops and regulatory/financial issues.